Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma

NCT02584920 is registered in ClinicalTrials.gov with Shanghai Henlius Biotech as lead sponsor.

NCT NCT02584920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02584920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma
Lead sponsor
Shanghai Henlius Biotech
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2014
Completion date
August 31, 2015
Enrollment
87 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell non hodgkin's lymphoma